

The 9th European Congress of Endocrinology, in Budapest, Hungary,
28 April – 2 May 2007


Papp László Budapest Sportaréna
Budapest, Hungary
Saturday, 28 April 2007
(15:30h – 17:00h)

WorldWIDE Satellite Symposium

Natural approaches to improving blood glucose control: a focus on Type 2 diabetes care

Proposed Educational Objectives

- Understand the challenges and problems of obtaining good blood glucose control
- Understand the physiological role of gut peptides in blood glucose control
- Review pathophysiological impact of impaired gut peptide activity in Type 2 diabetes on:
 - Insulin secretion
 - Glucagon secretion
 - Secondary effects together with their effects on blood glucose control
- Discuss new ways of ameliorating these problems in Type 2 diabetes
 - Gut peptide agonists
 - Inhibitors of gut peptide metabolism
- Design treatment strategies that capitalize on the unique properties of these 'incretin' therapies
 - Integration with current therapies
 - Safety and tolerance profiles
 - Body weight control
 - Speculative advantages (progression delay of Type 2 diabetes)



Agenda

Chair: Professor Philip Home (Newcastle, UK)

Time	Topic	Faculty
15.30 – 15:35	Welcome and introduction <ul style="list-style-type: none">• Learning Objectives	Professor Philip Home Newcastle University Newcastle upon Tyne, UK
15.35 – 15.45	Challenges and importance of achieving blood glucose control targets in Type 2 diabetes <ul style="list-style-type: none">• The problem of diabetes care and good glycaemic control• Recent data on complication of diabetes and their relation to hyperglycaemia• Importance of basal and postprandial glycaemic control in the management of Type 2 diabetes• Normal and abnormal insulin secretion	Dr Jaime A. Davidson Programme Co-Chair Clinical Associate Professor of Internal Medicine University of Texas Southwestern Medical Center Dallas Southwestern Medical School Dallas, Texas, USA
15.45 – 16.05	Normal regulation of insulin and glucagon secretion and its disturbance in Type 2 diabetes <ul style="list-style-type: none">• Physiological regulation by GLP-1• Abnormalities of the incretin system in Type 2 diabetes• Effects of GLP-1 administration in Type 2 diabetes<ul style="list-style-type: none">– Primary effects on insulin and glucagon secretion– Secondary effects on glucose and metabolic control– Effects on body weight• Effects of GLP-1 on islet cell mass and turnover	Professor Dr Robert J. Heine Diabetes Center VU University Medical Center, Amsterdam, The Netherlands
15.05 – 16:25	Islet function enhancers: novel therapeutic options for the management of Type 2 diabetes <ul style="list-style-type: none">• GLP-1 agonists and DPP-4 inhibitors<ul style="list-style-type: none">– Mechanisms of action– Clinical efficacy– Secondary therapeutic benefits– Safety profiles	Professor Dr Juris J. Meier University Hospital St. Josef-Hospital Ruhr-University Bochum, Germany
16:25 – 16:45	Practical application of emerging therapies: a case-based discussion <ul style="list-style-type: none">– Sub-optimal glucose control on metformin– Deteriorating glucose control on oral combination therapy	Dr Jaime A. Davidson
16:45 – 17:00	Questions, answers, and wrap up	Panel